Category: Covidien
William Blair & Co. added 20% to its stake in medical device company NxStage Medical, which makes home hemodialysis equipment.
William Blair & Co. added 20% to its holdings in NxStage Medical (NSDQ:NXTM) last year, according to regulatory filings.
The Chicago-based investment bank owned more than 3.8 million NXTM shares as of Dec. 31, 2012, up 19.5% from the 3.2 million shares it owned at the close of 2011.
Covidien makes progress on its long-anticipated split into separate medical device and pharmaceutical businesses, incorporating the Mallinckrodt drug company in Ireland.
Healthcare giant Covidien (NYSE:COV) issued updates on its long-awaited split into separate medical device and drug units and incorporated the Mallinckrodt pharmaceutical division as an independent entity in Ireland.
Novation picks up new product lines from Teleflex, Covidien and others.
Hedge fund goliath BlackRock Inc. boosts its stake in a bevy of medical device companies.
BlackRock Inc., 1 of the world's largest hedge funds, boosted its stake in a clutch of medical device companies, with 1 exception.
Medical device company Covidien increases its guidance for 2013 on above-market growth in its medical device sales and a rosy outlook on emerging markets.
Medtech titan Covidien (NYSE:COV) gained some points on Wall Street after raising its 2013 sales outlook on the strength of its 1st quarter results and an optimistic outlook on the company's emerging market potential.
Medical device maker Covidien wins CE Mark approval in the European Union for its EverFlex self-expanding stent system.
Medical device company Covidien (NYSE:COV) announced CE Mark approval in the European Union for its EverFlex self-expanding peripheral stent as well as for the accompanying Entrust delivery system.
Covidien plans to roll out the device in Western Europe next month, according to a press release.
Covidien launches the Swift prime study, 1 of the largest studies to examine acute ischemic stroke.
Covidien (NYSE:COV) enrolled the 1st patient in the Swift Prime study, a multi-center, randomized, controlled trial of its Solitaire FR revascularization device for restoring blood flow to the brain.
